Kaspar Binz

Kaspar Binz has a strong background in the life science industry. In 2019, they founded and became the CEO of Binz Biotech Consulting, a company that provides consultancy services for biotech companies in areas such as corporate strategy, R&D strategy, and fundraising. In 2022, they co-founded arcoris bio AG and served as the Chairman of the board of directors. Kaspar also became a Board Member of Alithea Genomics during the same year. In 2023, they joined ETH Zürich as an ETH Startup Coach. Prior to these roles, Kaspar Binz co-founded Molecular Partners AG in 2004 and held various positions within the company, including Vice President and CSO & Executive Director. Kaspar also served on the Board of Directors, where they were responsible for defining corporate strategy and securing funding. Kaspar Binz began their career in academia, completing a PhD and PostDoc at the University of Zurich from 1999 to 2004.

Kaspar Binz received their education in a chronological manner, starting in 1996. Kaspar pursued a Bachelor's degree in Biotechnology at the Université Louis Pasteur (Strasbourg I), which they completed in 1999. During the same period, they also obtained a Diplôme d'Études Approfondies (DEA) in Biotechnology from the same institution.

In 1999, Kaspar Binz briefly attended KTH Royal Institute of Technology, where they pursued a Master of Science (M.Sc.) degree in Biochemistry. However, their time at KTH was limited to that year.

From 1999 to 2004, Kaspar Binz attended the University of Zurich, where they completed their Doctor of Philosophy (PhD) in Designed Ankyrin Repeat Proteins as Alternatives to Antibodies. Their doctoral program provided him with a comprehensive understanding of this field of study.

Overall, Kaspar Binz's education history reveals a well-rounded background in biotechnology, biochemistry, and designed ankyrin repeat proteins.